Table 1.
Characteristics of the Analyzed Population (N = 127)
| Characteristic | Median (Range) or Percentage |
|---|---|
| Age at entry, y | 29 (18–38) |
| Race | |
| Black | 61 |
| White | 30 |
| Other or unknown | 9 |
| Ethnicity | |
| Hispanic | 34 |
| Non-Hispanic | 63 |
| Unknown | 3 |
| CD4 count at entry, cells/mm3 | 472 (28–1383) |
| CD4 percentage at entry | 31 (1–53) |
| CD8 count at entry, cells/mm3 | 680 (247–1951) |
| CD8 percentage at entry | 46 (18–75) |
| HIV load at entrya | |
| HIV load at entry, copies/mL | 75 (40–294 200) |
| Percentage with ≤50 copies/mL | 35 |
| Percentage with ≤400 copies/mL | 79 |
| Antiretroviral therapyb | |
| HAARTc | 94 |
| Non-HAART | 6 |
| Gestational age at entry, wk | 26 (14–34) |
| Seasonal influenza vaccination | 31d |
| Delivery characteristic (n = 125) | |
| Cesarean | 54 |
| Preterm (26–36 wk) | 14 |
| Vertical transmission of HIV infection | 1e |
Abbreviations: HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus.
a HIV load values below the limit of detection were replaced with the lower limit of the assay used for each subject.
b Prior to or at the initial vaccine visit.
c HAART is defined as ≥3 medications from ≥2 antiretroviral classes.
d Thirty-five subjects received inactivated seasonal influenza vaccine 14–30 days before study vaccine dose 1, and 5 between 21 days after study vaccine dose 2 and study end.
e One infant was confirmed to be HIV-infected during the period of infant follow-up.